Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease

Nosratola D Vaziri1

  • 1Division of Nephrology and Hypertension, Department of Medicine, University of California, Irvine, California, USA. ndvaziri@uci.edu

Insights

Chronic kidney disease (CKD) accelerates atherosclerosis by altering lipid metabolism and high-density lipoprotein (HDL) function. These changes promote cardiovascular disease and kidney damage, even with standard treatments.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Lipid Metabolism

Background:

  • Chronic kidney disease (CKD) significantly increases cardiovascular disease (CVD) risk.
  • CKD is linked to inflammation, oxidative stress, and dyslipidemia, driving atherosclerosis.
  • CKD dyslipidemia involves low HDL, impaired HDL function, and altered lipoprotein profiles.

Purpose of the Study:

  • To review the impact of CKD on HDL structure and function.
  • To examine lipid metabolism pathways in CKD affecting the kidney and vasculature.
  • To discuss the limitations of current therapies in managing CKD-associated CVD.

Main Methods:

  • Review of existing literature on CKD, dyslipidemia, and atherosclerosis.
  • Analysis of lipid accumulation in rat models of CKD.
  • Examination of molecular pathways regulating lipid transport and metabolism in CKD.

Main Results:

  • CKD induces lipid accumulation in kidneys and aortas of rats.
  • Lipid accumulation is mediated by altered expression of lipid transport and metabolism proteins.
  • Impaired HDL function and dysregulated lipid pathways promote atherosclerosis and kidney damage.

Conclusions:

  • CKD profoundly affects HDL and lipid metabolism, contributing to CVD and kidney disease progression.
  • Statins and antioxidants have limited efficacy in end-stage renal disease populations.
  • Understanding these pathways is crucial for developing targeted therapies for CKD-associated cardiovascular complications.

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...